Table 3. . Tumor response.
| TACE + B (WT) | TACE + B (mut) | TACE (WT) | TACE (mut) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 month | 3 months | 6 months | 1 month | 3 months | 6 months | 1 month | 3 months | 6 months | 1 month | 3 months | 6 months | |
| CR | 33 | 42 | 36 | 0 | 4 | 4 | 0 | 8 | 11 | 0 | 11 | 25 |
| PR | 50 | 33 | 27 | 84 | 64 | 36 | 41 | 15 | 28 | 30 | 11 | 25 |
| SD | 17 | 25 | 0 | 16 | 28 | 36 | 41 | 42 | 17 | 30 | 0 | 0 |
| PD | 0 | 0 | 9 | 0 | 4 | 24 | 19 | 35 | 44 | 40 | 78 | 50 |
| DCR | 100 | 100 | 91 | 100 | 96 | 76 | 82 | 65 | 56 | 60 | 22 | 50 |
| p-values | 1 month | 3 months | 6 months | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TACE-B (WT) vs TACE (WT) | < 0.001† | < 0.001† | < 0.001† | |||||||||
| TACE-B (mut) vs TACE (mut) | < 0.001† | < 0.001† | 0.031905† | |||||||||
| TACE-B (WT) vs TACE-B (mut) | // | 0.043352† | 0.00427† | |||||||||
| TACE (WT) vs TACE (mut) | 0.000607 | < 0.001† | 0.395292 |
†
p < 0.05.
B: Bevacizumab; CR: Complete response; DCR: Disease control rate; mut: Mutated; PD: Progressive disease; PR: Partial response; SD: Stable disease; TACE: Transarterial chemoembolization; WT: KRAS wild-type.